Background/Aims: Elevated parathyroid hormone (PTH) is used to diagnose high turnover bone disease in chronic kidney disease (CKD). The diagnostic accuracy of PTH in kidney transplant recipients with CKD is unknown. Methods: We examined kidney transplant recipients with CKD stages 3 (n = 498) and 4 (n = 141) to determine the sensitivity and specificity of the Kidney/Dialysis Outcome Quality Initiative (K/DOQI)-recommended PTH levels in detecting elevated serum β-CrossLaps (CTX) or osteocalcin (OC) levels. We performed receiver-operator curve analyses to determine CKD stage-specific PTH levels that provide optimal diagnostic accuracy. Results: PTH below the lower limits of the K/DOQI ranges (35 and 70 pg/ml in CKD stages 3 and 4, respectively) showed sensitivity of >90% in diagnosing increases in biochemical markers. The upper limits (70 and 110 pg/ml), however, showed poor specificity. A specificity of >90% for detecting increased biochemical markers was seen with PTH of >140 and >240 pg/ml in CKD stages 3 and 4, respectively. Conclusion: Currently applied cutoffs for PTH in kidney transplant recipients with CKD stages 3 and 4 do not appear to adequately detect increased biochemical markers of bone turnover. Diagnostic uncertainty exists in patients with CKD stage 3 and PTH between 35 and 140 pg/ml, and CKD stage 4 and PTH between 70 and 240 pg/ml.

Keywords:
Parathyroid hormone, High turnover bone disease, Kidney transplant, Chronic kidney disease
1.
Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31–38.
2.
De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM: The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002;13:2762–2769.
3.
Fellner SK, Lang RM, Neumann A, Bushinsky DA, Borow KM: Parathyroid hormone and myocardial performance in dialysis patients. Am J Kidney Dis 1991;18:320–325.
4.
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208–2218.
5.
Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771–780.
6.
Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131–2138.
7.
Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008;73:1296–1302.
8.
Quarles LD, Lobaugh B, Murphy G: Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75:145–150.
9.
Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure – an evolving disorder. Kidney Int 1993;43:436–442.
10.
Solal ME, Sebert JL, Boudailliez B, Marie A, Moriniere P, Gueris J, Bouillon R, Fournier A: Comparison of intact, midregion, and carboxy-terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 1991;73:516–524.
11.
Eknoyan G, Levin A, Levin N: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:1–201.
12.
Karthikeyan V, Karpinski J, Nair RC, Knoll G: The burden of chronic kidney disease in renal transplant recipients. Am J Transplant 2004;4:262–269.
13.
Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH: High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000;11:1093–1099.
14.
Torres A, Rodriguez AP, Concepcion MT, Garcia S, Rufino M, Martin B, Perez L, Machado M, de Bonis E, Losada M, Hernandez D, Lorenzo V: Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 1998;13(suppl 3): 94–97.
15.
Velasquez-Forero F, Mondragon A, Herrero B, Pena JC: Adynamic bone lesion in renal transplant recipients with normal renal function. Nephrol Dial Transplant 1996;11(suppl 3):58–64.
16.
Sadideen H, Covic A, Goldsmith D: Mineral and bone disorder after renal transplantation: a review. Int Urol Nephrol 2008;40:171–184.
17.
Sperschneider H, Stein G: Bone disease after renal transplantation. Nephrol Dial Transplant 2003;18:874–877.
18.
Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C: Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995;80:864–868.
19.
Power MJ, Fottrell PF: Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci 1991;28:287–335.
20.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461–470.
21.
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1–S266.
22.
Bablok W, Passing H, Bender R, Schneider B: A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry. Part III. J Clin Chem Clin Biochem 1988;26:783–790.
23.
Schmidt-Gayk H, Spanuth E, Kotting J, Bartl R, Felsenberg D, Pfeilschifter J, Raue F, Roth HJ: Performance evaluation of automated assays for β-CrossLaps, N-MID-osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). Clin Chem Lab Med 2004;42:90–95.
24.
Magnusson P, Sharp CA, Magnusson M, Risteli J, Davie MW, Larsson L: Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int 2001;60:257–265.
25.
Suwelack B, Gerhardt U, Witta J, Hillebrandt U, Hohage H: Effect of parathyroid hormone levels on carotid intima-media thickness after renal transplantation. Am J Hypertens 2001;14:1012–1018.
26.
Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P: Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006;70:345–350.
27.
Barreto FC, Barreto DV, Moyses RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB: K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008;73:771–777.
28.
Qi Q, Monier-Faugere MC, Geng Z, Malluche HH: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995;26:622–631.
29.
Kovesdy CP, Kalantar-Zadeh K: Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol 2008;40:427–440.
30.
Julian BA, Quarles LD, Niemann KM: Musculoskeletal complications after renal transplantation: pathogenesis and treatment. Am J Kidney Dis 1992;19:99–120.
31.
Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S: Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988;123:2571–2577.
32.
Schlosberg M, Movsowitz C, Epstein S, Ismail F, Fallon MD, Thomas S: The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 1989;124:2179–2184.
33.
Briner VA, Thiel G, Monier-Faugere MC, Bognar B, Landmann J, Kamber V, Malluche HH: Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25-vitamin D levels two years after kidney transplantation. Transplantation 1995;59:1393–1400.
34.
Carlini RG, Rojas E, Arminio A, Weisinger JR, Bellorin-Font E: What are the bone lesions in patients with more than four years of a functioning renal transplant? Nephrol Dial Transplant 1998;13(suppl 3):103–104.
35.
Sanchez CP, Salusky IB, Kuizon BD, Ramirez JA, Gales B, Ettenger RB, Goodman WG: Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 1998;53:1358–1364.
36.
Lehmann G, Ott U, Stein G, Steiner T, Wolf G: Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant Proc 2007;39:3153–3158.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.